Netakimab is a chimeric, humanized monoclonal antibody targeting IL17A, containing a Lama glama VHH derivative domain and a VL variable domain, with potential use in autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis and other inflammatory diseases.